The replacement of saturated fatty acids (SFA) has been the mainstay of our dietary guidelines to help prevent cardiovascular disease (CVD) for over 30 years. However, the underlying evidence to support this guideline is now held in contentious disrepute on the grounds of an apparent lack of evidence, largely from meta-analyses, for a direct relationship between saturated fat and CVD mortality. This can be explained by the fact that the relationship between dietary SFA and CVD is not direct, but indirect and mediated through the low-density lipoprotein cholesterol (LDL-C) raising effects of certain SFA, in certain foods. There is over 100 years of evidence to link raised serum cholesterol with CVD and to support the current consensus that serum LDL is causally related to CVD morbidity and mortality. Nevertheless, the role of LDL as a biomarker of CVD risk, as measured by its cholesterol content (LDL-C), is often confused with its contribution to cardio-metabolic risk by its conversion into small and dense LDL particles with increased potential to cause CVD. The clinical utility of serum LDL is outstanding as a biomarker for CVD, albeit through an increase in its cholesterol mass (LDL-C), its small particle size or over-abundance of these particles. What is of overriding importance is to identify and modify these characteristics in LDL at the earliest stage of their development and to reduce the associated CVD risk through appropriate and sustained changes in diet and lifestyle.
Introduction
In 2015, diet was ranked above tobacco as the top risk factor for cardiovascular disease (CVD), as measured by disability-adjusted life years (DALYs) , that is, years of life lost through disability and premature death (Newton et al. 2015; Fig. 1) . This impressive accolade can be attributed to multiple factors, not least of which includes human recidivism in sustaining a healthy diet and the stark reality that human nutrition has never been high on the agenda at medical school. In comparison with medicine, nutrition is regarded as a relatively imperfect science that relies on evidence for associations between diet and disease from observational epidemiology and prospective cohort studies, the outcomes of which can be subject to confounding by complex, uncontrolled conditions and the vagaries of human behaviour over time.
Evidence for causality is often indirect, being derived from the effects of diet on biomarkers of disease rather than hard, clinical endpoints. These limitations make nutritional science more difficult to interpret and less diagnostically accurate and precise than medical science. Dietary guidelines must be formulated on a consensus of the totality of evidence across a broad range of different types of study. An unfortunate side effect of any change in the balance of evidence supporting these guidelines is the common misperception that this represents a contradictory swing of expert opinion on what is good or bad nutrition in relation to the risk of disease. 'It's now okay to eat fat' and 'Butter is back' are two such examples for saturated fat and CVD from a national tabloid. These headlines sell newspapers but undermine confidence in dietary guidelines and erode trust in nutritional science.
Serum biomarkers as indirect indicators of cardiovascular disease risk
A major advance in biomedical nutritional science in the last 50 years has been the application of serum biomarkers as surrogates of otherwise unmeasurable endpoints of disease in diet trials. Biomarkers also underpin the concept of disease risk susceptibility; that is the recognition of subclinical metabolic dysfunction that would otherwise lie silent and undetected, but which is more likely to be responsive to therapeutic diet and lifestyle changes than chronic disease. This advance has helped researchers to overcome the limitation of trying to establish the biological effects of individual nutrients by studying the impact of experimental diets in groups of 'normal', healthy individuals with adaptive, metabolic flexibility to resist the effects of dietary change.
Two of the most well-established biomarkers that are causally related to the onset, progression and endpoints of CVD are blood pressure and serum low-density lipoprotein cholesterol (LDL-C). These biomarkers have been key targets for therapeutic lifestyle changes to reduce CVD risk for many years, the most important of which includes the recommendations to reduce the intake of salt and saturated fatty acids (SFA), respectively (Public Health England 2016). However, while the recommendation to reduce a high intake of salt to lower the incidence of stroke and CVD mortality is widely accepted, the same cannot be said for the recommendations to reduce SFA. Serious dispute has arisen over the link between dietary SFA and CVD risk, chiefly from the failure of meta-analyses to show a direct relationship between SFA and CVD mortality, in prospective cohort and intervention studies (Chowdhury et al. 2014; Harcombe et al. 2016) . These findings can be explained by the fact that SFA is indirectly, not directly, related to CVD through its effects on raising serum LDL-C. This situation is analogous to the indirect effect of salt on CVD through raising blood pressure, though the relationship between dietary SFA and raised serum LDL-C is more Figure 1 Disability-adjusted life years (DALY) attributed to level 2 risk factors in 2013 in England for both men and women combined (Source: Newton et al. 2015) . [Colour figure can be viewed at wileyonlinelibrary.com] complex and variable between individuals than the physiological effects of excess salt on the vascular system.
When the UK government first introduced its guidelines to reduce saturated fat intake to 10% of total energy in 1983 (Robbins 1983) , it did so on the basis of two pieces of scientific evidence. The first was that raised serum LDL-C was associated with increased CVD risk and mortality, for which there is now over 100 years of supporting evidence, leading to a consensus from the European Atherosclerosis Society in 2017 that serum LDL is causally related to atherosclerotic CVD (Ference et al. 2017) . The second piece of evidence was that dietary SFA raise the serum concentration of LDL, which in turn increases CVD risk. This 'diet-heart' hypothesis has always been controversial, in part, because it is more difficult to interpret and assimilate the substantive amounts of supportive evidence. This evidence spans from early metabolic ward studies in the 1950s, which showed that a controlled substitution of dietary SFA with unsaturated fatty acid lowered serum cholesterol, to Nobel-prize winning science that led to the discovery of the LDL-receptor pathway that helped to identify the mechanism by which dietary SFA and polyunsaturated fatty acids (PUFA) raise and lower serum LDL-C, respectively. There is also evidence to support a direct association between the substitution of dietary SFA with PUFA and reduced CVD mortality, though in many cases this evidence has been confounded by extreme and uncontrolled study designs (Steinberg 2013) .
Controversy over the founding evidence for the diet-heart hypothesis The nutritional epidemiologist, Ancel Keys has been accused of falsifying his data to produce a positive curvilinear relationship between the intake of energy from dietary SFA and death from CVD in his classic Seven Countries Study (Keys et al. 1966) . Nevertheless, his epidemiological findings were in complete accord with the definitive demonstration that SFA tends to raise, while PUFA tends to lower, serum cholesterol in humans, in rigorously controlled metabolic ward studies in the 1950s (Kinsell et al. 1952; Ahrens et al. 1954) . This early foresight into the differential effects of SFA, chiefly from animal fats, and PUFA from vegetable sources, on serum cholesterol came soon after the discovery of a specific fraction of cholesterol (beta-lipoprotein) that was found to be associated with the development of coronary atherosclerosis (Gofman 1950) , and was later identified as the serum lipoprotein that was responsive to changes in dietary fat, namely LDL.
Keys went on to develop equations for predicting the serum cholesterol response to changes in the relative proportions of dietary SFA and PUFA, which have been used in various forms in clinical practice for over 50 years. However, his work has been largely discredited on the grounds that he excluded data points from the analysis of what became the Seven Countries Study. This apparent misconduct not only undermines Keys' remarkable achievement in helping to establish the diet-heart hypothesis, but is also used to support the contentious and, on balance, scientifically unfounded view that a high intake of dietary SFA is unrelated to CVD.
The diet-heart hypothesis: Limitations of meta-analyses A purpose of secondary meta-analysis, from a nutritional perspective, is to provide the statistical power to show a significant relationship between a dietary factor and endpoint of disease, which lies beyond the capability of the individual primary studies. However, when the outcome of a meta-analysis is inconsistent with the outcome of its individual primary studies, this suggests that something or, in the case of meta-analysis of SFA and CVD, many things are wrong. Firstly, the statistical modelling in meta-analysis takes no account of what SFA is being replaced with. For example, when SFA is replaced with PUFA, there is good evidence that this exchange lowers CVD risk by lowering serum LDL-C. Conversely, when SFA is replaced with carbohydrates, chiefly sugars, this may increase CVD risk. It is possible that the combination of these positive and negative effects explain the net finding of there being no association between of SFA and CVD mortality. Secondly, the effect is confounded by the nature of the foods that contain the SFA, as the effect of SFA on LDL-C varies between different foods; for example the lesser effects of SFA on LDL-C in fermented dairy foods, such as cheese, relative to butter (Brassard et al. 2017) . Thirdly, specific SFA have different effects on serum LDL-C. When the component primary studies that have been affected by these factors are removed from the meta-analysis, as for example the positive and negative confounding effects of SFA from dairy and trans fatty acids, a significant association between dietary SFA and CVD mortality emerges (Siri-Tarino et al. 2015) . The same primary studies have been examined in a recent Cochrane systematic review and meta-analysis that confirmed the lack of an association between increased intake of SFA and CVD mortality (Hooper et al. 2015) . However, this study did show that replacement of dietary SFA with PUFA was associated with a 27% reduction in cardiac events, which takes effect when the contribution of dietary SFA to total energy intake exceeded 10%.
Translating the risk associated with lowdensity lipoprotein to prolong life and delay death
The recent consensus on LDL being causally related to cardiovascular atherosclerosis provides further justification for basing dietary recommendations on the effects of dietary SFA on a single biomarker (LDL), but how does this translate to prolonging life and delaying death? The serum cholesterol-lowering effect of reducing SFA intake by 2% (from current intakes of approximately 12% to 10% of total energy intake) has been estimated to prevent or delay the onset of death from CVD death in approximately 3000 people in England. Alternatively, the burden of CVD that can be attributed to raised serum LDL-C in England is about 5%, that is about 90 000 DALYs. This can be compared to 11% of CVD burden (~200 000 DALYs) from dietary risks (low intake of fruit and vegetables, wholegrain, nuts and seeds, milk, fibre and seafood n-3 and n-6 PUFA, and high intake of red and processed meat, sugars, sugars-sweetened beverages, trans fats, sodium and sub-optimal intake of calcium) (Newton et al. 2015 ; Fig. 1 ). Although the need to reduce dietary SFA is surprisingly absent from this list, replacing 2% energy from SFA with dietary PUFA will make a significant contribution to lowering serum LDL-C and reducing death from CVD, as indicated above. How does this translate into benefit for cardiovascular health for an individual? Well, if you are a non-smoker, have a BMI <25, are physically active and adopt a Mediterranean diet, you could supposedly gain a minimum of 2 years of life without disability or premature death from CVD. If you make the crude assumption that these factors equate to contributions from tobacco, raised systolic blood pressure and serum cholesterol, and a poor diet to CVD, which correspond to an approximate total of 30% of CVD burden, then lowering serum cholesterol alone should buy you about 4 months of life. A small consolation for a lifelong change in your diet, but an invaluable and worthwhile extension of life nonetheless.
Making sense of cardiovascular disease risk arising from raised serum low-density lipoprotein within populations and individuals Most people with moderately raised serum LDL-C (e.g. 2.5-4.5 mmol/l) do not succumb to premature CVD and, conversely, most people who do succumb to CVD do not have raised serum LDL-C. Increased serum LDL confers risk for increased CVD morbidity and mortality, but the expression and management of this risk must be placed in perspective of what it represents to an individual or a population. The absolute risk (number of CVD deaths) associated with a moderate level of LDL-C is relatively low in comparison with the absolute risk associated with a high level (e.g. >7.8 mmol/l) in populations. However, the risk that can be 'attributed' to serum LDL at a moderate level is much higher than it is at a high level because most people have moderate LDL-C levels and fewer people have high levels, and attributable risk is a product of the absolute risk multiplied by the frequency of that risk factor. There are other forms of CVD risk which have significantly greater attributable risk because they are much more common in populations; this includes cardio-metabolic risk in the highly prevalent conditions of central obesity and type 2 diabetes.
LDL also plays a major role as a biomarker of cardio-metabolic risk, as a result of a decrease in its particle size and density and increased abundance of these small, dense LDL (sdLDL) particles in serum and not through its cholesterol content (LDL-C). Cardio-metabolic risk consists of a constellation of metabolically related biomarkers of dysfunction in glucose and lipid metabolism and the vascular system. These risk factors have multi-factorial origins, but are intimately associated with storage of excess visceral fat in the abdomen and ectopic fat in key metabolic tissues such as liver, pancreas, skeletal and heart muscle (Mathieu et al. 2014) . The dyslipidaemia that characterises cardiometabolic risk is known as an atherogenic lipoprotein phenotype and consists of a moderately raised serum triacylglycerol (>1.5 mmo/l), a low high-density lipoproteins (HDL) (<1.0 mml/l) and predominance of sdLDL, the latter of which expresses altered metabolic properties and increased potential to promote atherosclerosis. sdLDL can be measured by many different methods, which commonly identify two or more LDL-subclass patterns consisting of predominantly larger LDL particle than normal (normal pattern 'A') or sdLDL (abnormal pattern 'B') (Griffin 1995 ; Fig. 2) . Pattern 'B' may or may not be accompanied by an increase in the number of small LDL particles as measured by the LDL-apoprotein B content. This condition is known as hyperapo b-lipoproteinaemia and is associated with a substantial increase in CVD risk (Sniderman 2002) . These serum biomarkers can be modified by diet and lifestyle factors ( Table 1 ). The concentration of serum triacylglycerol (TAG) is a critical determinant of the formation of sdLDL, especially in the postprandial phase. Elevation in serum TAG to >1.5 mmol/l promotes the remodelling of LDL into sdLDL and, conversely, reducing serum TAG <1.5 mmol/l promotes the redistribution of LDL subclasses into larger particles.
Clarification of the effects of dietary saturated fatty acids on large low-density lipoprotein
It has been suggested that dietary SFA has no effect on CVD mortality because it only affects larger LDL particles, which are unrelated to CVD risk. This reveals a clear misunderstanding of how dietary SFA influences CVD risk by affecting LDL particle size, and the respective roles of serum LDL-C and LDL subclasses as biomarkers of cholesterol-mediated and cardio-metabolic CVD risk.
Raised serum LDL-C and cardio-metabolic risk factors are not mutually exclusive and frequently coexist, as for example under conditions of obesity, excess bodyweight and in type 2 diabetes. However, the nature of the LDL particles that contribute to raised serum LDL-C will differ depending on the presence of other cardio-metabolic risk factors and, in particular, the presence of raised serum TAG, or whether the elevation in serum LDL-C is an isolated hypercholesterolaemia. If serum TAG is elevated above 1.5 mmol/l there will be an increase in the relative proportion sdLDL particles (LDL-III, IV; Fig. 2) , whereas in the case of isolated hypercholesterolaemia the LDL particles will be larger (LDL-II). In both situations, LDL, whether small or large, confers increased CVD risk, either through its total mass, as reflected by its concentration of cholesterol or it altered metabolic properties ( Table 1 ). The metabolic origin for the overproduction of sdLDL particles, as measured by an increase in serum LDL-apo B (hyperapo-b-lipoproteinaemia), is unclear, but has been shown to be relatively unresponsive to changes in dietary SFA in comparison with LDL-C (Lamantia et al. 2016) .
I strongly suspect that the idea that dietary SFA has no effect on CVD risk because it acts on large LDL has been deliberately misconstrued from the scientific literature to support the lack of evidence to link SFA with CVD mortality in meta-analysis. The LDL-Craising effect of dietary SFA is mediated, in part, through the suppression of LDL receptors, which facilitate the extraction of circulating LDL from the blood into cells. When serum LDL-C is elevated in the absence of raised serum TAG, the majority of LDL will be in the form of larger LDL-II (Fig. 2) . This subclass carries more cholesterol per particle than the other fractions and makes a significant contribution to the association between LDL-C and CVD risk, as illustrated in classic CVD mortality curves. LDL-II has also been shown to have the highest affinity for the LDL receptor. It follows that any dietary factor that influences LDL-receptor activity, such as dietary SFA, will exert a relatively greater effect on this LDL-II subclass. Therefore, in most people with isolated hypercholesterolaemia, dietary SFA will act on LDL that is relatively larger (LDL-II) than sdLDL (LDL-III), as the former type of LDL represents the predominant subclass, but to suggest that this effect has no impact on CVD risk is misleading. It ignores understanding about LDL-subclass physiology and the mechanisms by which dietary SFA influences LDL.
Diet and lifestyle strategies for the management of low-density lipoproteinmediated cardiovascular disease risk
The 'Portfolio diet' describes a combination of dietary measures with proven efficacy in lowering serum LDLcholesterol, which includes energy restriction to promote weight loss if necessary, replacing dietary SFA with PUFA and increasing dietary fibre. Plant sterols Figure 2 Distribution profiles of human serum LDL subclasses by density and particle size, as measured by density gradient ultracentrifugation and 2-16% gradient gel electrophoresis, respectively. LDL subclass profiles shown are of a healthy normolipidaemic female (----) and male (---), consisting of a predominance of large, light LDL particles (LDL-subclass pattern 'A'), and a patient with three-vessel coronary artery disease (---), consisting of a predominance of small, dense LDL (LDL-subclass pattern 'B') (Adapted with permission from Griffin 1995) .
and stanols are also important components of this portfolio diet but, while safe and effective in lowering LDL, these compounds have been contraindicated in some clinical guidelines, due to a lack of evidence that they reduce cardiac events and death from CVD. This would mean testing the efficacy of a food containing a sterol or stanol in a trial with these clinical endpoints, which is unfeasible for this or any other food containing a bioactive ingredient. Since the evidence that plant sterols and stanols reduce serum LDL-C in a dose-response fashion is unequivocal (Geleijnse & Trautwein 2014) , to exclude them from dietary guidelines to lower serum LDL-C and reduce CVD risk is negligent.
Cardio-metabolic risk mediated through sdLDL can be modified by reducing serum TAG. Qualitative changes to the diet that target the lowering of serum TAG, and attenuation of postprandial lipaemia, result in the remodelling of LDL into larger particles and an LDL-subclass pattern associated with lower CVD risk. The most potent macronutrients in this respect are the long-chain n-3 PUFA (EPA/DHA) from oily fish that lower serum TAG and increase LDL particle size (Griffin 2001) . Conversely, free sugars (sucrose and fructose) at high levels of intake (>20% energy) elevate serum TAG and postprandial lipaemia and promote the formation of sdLDL (Stanhope 2016) . The exchange of SFA for PUFA or MUFA has relatively minor effects on serum sdLDL in comparison with LDL-C, but may be beneficial in reducing other cardio-metabolic risk factors. Dietary effects on the number of sdLDL particles have been recently reviewed (Lamantia et al. 2016) . The modification of serum LDL-apo B, as a marker of increased LDL particle number, may require the combination of weight loss and physical activity, in addition to qualitative changes in dietary macronutrients.
Cardio-metabolic risk has a multi-factorial aetiology and for this reason its management and reduction will ultimately require multiple dietary changes, as can be found in the Mediterranean diet. This diet has proven efficacy in reducing CVD mortality as shown in the Table 1 Physiochemical properties of serum low-density lipoprotein (LDL) that increase its potential to promote cardiovascular atherosclerosis and increase cardiovascular disease risk, and possible dietary determinants/modifiers of these properties Table shows lipid phenotype and/or clinical condition associated with each LDL characteristic, the CVD risk associated with LDL characteristic and principal dietary determinants/modifiers of the LDL characteristic. CVD, cardiovascular disease; conc., concentration; HC, hypercholesterolaemia; apo B, apoprotein B; sdLDL, small dense low-density lipoprotein; hyperapo b, raised serum apoprotein B (predominance of sdLDL); C12-C16, fatty acid chain length 12 and 16 carbon atoms; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; EPA/DHA, eicosahexaenoic/docosahexaenoic acids; subclass pattern 'B', predominance of serum sdLDL; TAG, triacylglycerol renowned PREDIMED study (Estruch et al. 2013) . Many constituents of the Mediterranean diet may also produce favourable effects on LDL-C and sdLDL that are likely to exert additive or synergistic effects in reducing LDL-mediated CVD risk within a whole diet.
Conclusion, future challenges and opportunities
If saturated fat was on trial in a court of law, accused of causing death by CVD, would it be exonerated from the crime and allowed to go free? What is the strength of evidence to convict? It is clear that the accused did not act alone. There are countless suspects and circumstances related to the accused which are known to have contributed to the fatal event. Whether the crime was executed directly by the accused will remain unproven, but this is of less importance than the considerable weight of evidence to suggest that death was caused indirectly by a series of murder weapons, the main one of which is LDL. This 'weapon' has been implicated in this type of crime for many years. It can assault the victim in different ways, all of which contribute to the same endpoint of death, and has been incontrovertibly linked to the accused and the crime. I rest my case.
To prevent this crime in future, the atherogenicity of LDL must be reduced, either by lowering its cholesterol concentration in serum and/or by decreasing its cardio-metabolic potential, the choice of which will depend on the initial characteristics of LDL and the overall CVD risk profile of the individual.
A Holy Grail in nutritional science is to tailor specific dietary advice to the characteristics of an individual ('personalised nutrition') or groups of individuals ('precision nutrition'), to maximise benefits to health and reduce disease risk. This already operates in practice, by adjusting dietary advice according to the habitual dietary intake and physical and biochemical characteristics of an individual. Insight into the roles of genetic variation and nutrient-gene interactions is of fundamental importance in this respect, but has yet to impact on the dietary management of CVD risk. Within the limited context of LDL, it is possible to discriminate between CVD risk mediated through LDL-C or LDL subclasses, as sub-phenotypic markers of cardio-metabolic risk. However, the dietary response to the targeted management of these risk factors is highly variable between individuals because of inherent differences in our behaviour and biology. Unravelling the origins of biological variation in response to diets will be a major challenge for biomedical science. This will require a combination of imaging technologies to characterise fat depots, the trace-labelling of nutrients to evaluate metabolic fluxes, and metabolomics to provide a multivariate description of human metabolism that can identify a new generation of biomarkers of response to whole diets.
